Inorganic Nanoporous Membranes for Immunoisolated Cell-Based Drug Delivery

Mendelsohn, Adam; Desai, Tejal A.

doi:10.1007/978-1-4419-5786-3_10

Cited by 22 publications

(9 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such devices could reduce the risk of immunorejection of grafts without the requirement of immunosuppressive drug therapies. Moreover, such devices can potentially include provascularization factors or even be prevascularized prior to implantation in order to help circumvent the loss of graft mass due to inadequate oxygen supply . Such approaches are not necessarily new and indeed have been the focus of many commercial exploits over the years.…”

Section: Islet Transplantation and New Therapeutic Approachesmentioning

confidence: 99%

“…Such approaches are not necessarily new and indeed have been the focus of many commercial exploits over the years. Prominent examples include work by Newgard and colleagues in a joint effort with Gore Hybrid Technologies which generated chambers suitable for the implantation of immortal pancreatic beta‐cell xenografts into mouse models . Similarly, in 1999, Baxter Healthcare also reported success using a comparable apparatus, also to implant immortal xenogeneic beta‐cells in NOD mice .…”

Section: Islet Transplantation and New Therapeutic Approachesmentioning

confidence: 99%

See 1 more Smart Citation

Cellular models for beta‐cell function and diabetes gene therapy

2018

View full text Add to dashboard Cite

Diabetes is characterized by the destruction and/or relative dysfunction of insulin-secreting beta-cells in the pancreatic islets of Langerhans. Consequently, considerable effort has been made to understand the physiological processes governing insulin production and secretion in these cells and to elucidate the mechanisms involved in their deterioration in the pathogenesis of diabetes. To date, considerable research has exploited clonal beta-cell lines derived from rodent insulinomas. Such cell lines have proven to be a great asset in diabetes research, in vitro drug testing, and studies of beta-cell physiology and provide a sustainable, and in many cases, more practical alternative to the use of animals or primary tissue. However, selection of the most appropriate rodent beta cell line is often challenging and no single cell line entirely recapitulates the properties of human beta-cells. The generation of stable human beta-cell lines would provide a much more suitable model for studies of human beta-cell physiology and pathology and could potentially be used as a readily available source of implantable insulin-releasing tissue for cell-based therapies of diabetes. In this review, we discuss the history, development, functional characteristics and use of available clonal rodent beta-cell lines, as well as reflecting on recent advances in the generation of human-derived beta-cell lines, their use in research studies and their potential for cell therapy of diabetes.

show abstract

Section: Islet Transplantation and New Therapeutic Approachesmentioning

confidence: 99%

Section: Islet Transplantation and New Therapeutic Approachesmentioning

confidence: 99%

Cellular models for beta‐cell function and diabetes gene therapy

2018

View full text Add to dashboard Cite

show abstract

“…Encapsulated MIN-6 cells were shown to be responsive to different glucose concentrations, while IgG diffusion was significantly diminished. Titania porous membranes have been fabricated, and also benefit from tight nanometer pore size distributions, but unfortunately were not mechanically robust [272]. In a composite approach, Randall et al demonstrated that gold-coated self-folding porous membranes, made by lithographic patterning, could exhibit precisely controlled pore sizes based on the gold deposition duration (Fig.…”

Section: Cell Penetration Restrictive Devicesmentioning

confidence: 99%

Nanotechnology in cell replacement therapies for type 1 diabetes

Ernst

Bowers

Wang

et al. 2019

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Islet transplantation is a promising long-term, compliance-free, complication-preventing treatment for type 1 diabetes. However, islet transplantation is currently limited to a narrow set of patients due to the shortage of donor islets and side effects from immunosuppression. Encapsulating cells in an immunoisolating membrane can allow for their transplantation without the need for immunosuppression. Alternatively, "open" systems may improve islet health and function by allowing vascular ingrowth at clinically attractive sites. Many processes that enable graft success in both approaches occur at the nanoscale level-in this review we thus consider nanotechnology in cell replacement therapies for type 1 diabetes. A variety of biomaterial-based strategies at the nanometer range have emerged to promote immune-isolation or modulation, proangiogenic, or insulinotropic effects. Additionally, coating islets within nano-thin polymer films has burgeoned as an islet protection modality. Materials approaches that utilize nanoscale features manipulate biology at the molecular scale, offering unique solutions to the enduring challenges of islet transplantation.

show abstract

“…have developed a microfabricated membrane that can be incorporated into a device that both limits immune cell signaling and allows for adequate diffusion ( Fig. 18.2 ) ( [ 7,91,122,123,130 ] ). Nano-channels on the surface of the membrane allow for quick diffusion of glucose and other nutrients, yet inhibit transport of antibodies.…”

Section: Cell-based Drug Delivery Therapymentioning

confidence: 99%

Microtechnologies for Drug Delivery

Ainslie

Desai

2011

Long Acting Injections and Implants

View full text Add to dashboard Cite

Microfabrication techniques, originally developed in the microelectronics industry, can be engineered for in vivo drug delivery. Microfabrication uses a variety of techniques including photolithography and micromachining to create devices with features ranging from 0.1 to hundreds of microns with high aspect ratios and precise features. Microfabrication offers a device feature scale that is relevant to the tissues and cells to which they are applied, as well as offering ease of en masse fabrication, small device size, and facile incorporation of integrated circuit technology. Utilizing these methods, drug delivery applications have been developed for in vivo use through many delivery routes including intravenous, oral, and transdermal. Overall, microfabricated devices have had an impact over a broad range of therapies and tissues. This review addresses many of these devices and highlights their fabrication as well as discusses materials relevant to microfabrication techniques.

show abstract

Inorganic Nanoporous Membranes for Immunoisolated Cell-Based Drug Delivery

Cited by 22 publications

References 101 publications

Cellular models for beta‐cell function and diabetes gene therapy

Cellular models for beta‐cell function and diabetes gene therapy

Nanotechnology in cell replacement therapies for type 1 diabetes

Microtechnologies for Drug Delivery

Contact Info

Product

Resources

About